511 – Outcomes Among People With Viraemia While on Dolutegravir-Based ART in a Large Prospective Cohort
Background The WHO and multiple countries in resource limited settings recommend switch to ritonavir boosted protease inhibitor (PI) after two consecutive HIV viral loads (VL) ≥1000 copies/mL while on a dolutegravir (DTG) based regimen without the requirement for a drug resistance test (DRT). There is limited data to support this strategy. Methods Ndovu is a…